155 related articles for article (PubMed ID: 16504646)
1. The cannabinoid CB1 receptor antagonist rimonabant attenuates the hypotensive effect of smoked marijuana in male smokers.
Gorelick DA; Heishman SJ; Preston KL; Nelson RA; Moolchan ET; Huestis MA
Am Heart J; 2006 Mar; 151(3):754.e1-754.e5. PubMed ID: 16504646
[TBL] [Abstract][Full Text] [Related]
2. Blockade of effects of smoked marijuana by the CB1-selective cannabinoid receptor antagonist SR141716.
Huestis MA; Gorelick DA; Heishman SJ; Preston KL; Nelson RA; Moolchan ET; Frank RA
Arch Gen Psychiatry; 2001 Apr; 58(4):322-8. PubMed ID: 11296091
[TBL] [Abstract][Full Text] [Related]
3. Single and multiple doses of rimonabant antagonize acute effects of smoked cannabis in male cannabis users.
Huestis MA; Boyd SJ; Heishman SJ; Preston KL; Bonnet D; Le Fur G; Gorelick DA
Psychopharmacology (Berl); 2007 Nov; 194(4):505-15. PubMed ID: 17619859
[TBL] [Abstract][Full Text] [Related]
4. Antagonist-elicited cannabis withdrawal in humans.
Gorelick DA; Goodwin RS; Schwilke E; Schwope DM; Darwin WD; Kelly DL; McMahon RP; Liu F; Ortemann-Renon C; Bonnet D; Huestis MA
J Clin Psychopharmacol; 2011 Oct; 31(5):603-12. PubMed ID: 21869692
[TBL] [Abstract][Full Text] [Related]
5. CB1 - cannabinoid receptor antagonist effects on cortisol in cannabis-dependent men.
Goodwin RS; Baumann MH; Gorelick DA; Schwilke E; Schwope DM; Darwin WD; Kelly DL; Schroeder JR; Ortemann-Renon C; Bonnet D; Huestis MA
Am J Drug Alcohol Abuse; 2012 Jan; 38(1):114-9. PubMed ID: 21797816
[TBL] [Abstract][Full Text] [Related]
6. Peripheral selectivity of the novel cannabinoid receptor antagonist TM38837 in healthy subjects.
Klumpers LE; Fridberg M; de Kam ML; Little PB; Jensen NO; Kleinloog HD; Elling CE; van Gerven JM
Br J Clin Pharmacol; 2013 Dec; 76(6):846-57. PubMed ID: 23601084
[TBL] [Abstract][Full Text] [Related]
7. Synthetic cannabinoids found in "spice" products alter body temperature and cardiovascular parameters in conscious male rats.
Schindler CW; Gramling BR; Justinova Z; Thorndike EB; Baumann MH
Drug Alcohol Depend; 2017 Oct; 179():387-394. PubMed ID: 28846955
[TBL] [Abstract][Full Text] [Related]
8. Cardiovascular effects of 2-arachidonoyl glycerol in anesthetized mice.
Járai Z; Wagner JA; Goparaju SK; Wang L; Razdan RK; Sugiura T; Zimmer AM; Bonner TI; Zimmer A; Kunos G
Hypertension; 2000 Feb; 35(2):679-84. PubMed ID: 10679517
[TBL] [Abstract][Full Text] [Related]
9. Delta9-tetrahydrocannbinol accounts for the antinociceptive, hypothermic, and cataleptic effects of marijuana in mice.
Varvel SA; Bridgen DT; Tao Q; Thomas BF; Martin BR; Lichtman AH
J Pharmacol Exp Ther; 2005 Jul; 314(1):329-37. PubMed ID: 15831444
[TBL] [Abstract][Full Text] [Related]
10. Surinabant, a selective cannabinoid receptor type 1 antagonist, inhibits Δ9-tetrahydrocannabinol-induced central nervous system and heart rate effects in humans.
Klumpers LE; Roy C; Ferron G; Turpault S; Poitiers F; Pinquier JL; van Hasselt JG; Zuurman L; Erwich FA; van Gerven JM
Br J Clin Pharmacol; 2013 Jul; 76(1):65-77. PubMed ID: 23278647
[TBL] [Abstract][Full Text] [Related]
11. Local administration of delta9-tetrahydrocannabinol attenuates capsaicin-induced thermal nociception in rhesus monkeys: a peripheral cannabinoid action.
Ko MC; Woods JH
Psychopharmacology (Berl); 1999 Apr; 143(3):322-6. PubMed ID: 10353438
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of hippocampal acetylcholine release after acute and repeated Delta9-tetrahydrocannabinol in rats.
Carta G; Nava F; Gessa GL
Brain Res; 1998 Oct; 809(1):1-4. PubMed ID: 9795096
[TBL] [Abstract][Full Text] [Related]
13. Differential blockade of the antinociceptive effects of centrally administered cannabinoids by SR141716A.
Welch SP; Huffman JW; Lowe J
J Pharmacol Exp Ther; 1998 Sep; 286(3):1301-8. PubMed ID: 9732392
[TBL] [Abstract][Full Text] [Related]
14. Reduced neural response to reward following 7 days treatment with the cannabinoid CB1 antagonist rimonabant in healthy volunteers.
Horder J; Harmer CJ; Cowen PJ; McCabe C
Int J Neuropsychopharmacol; 2010 Sep; 13(8):1103-13. PubMed ID: 20426883
[TBL] [Abstract][Full Text] [Related]
15. Cannabinoid-induced tolerance is associated with a CB1 receptor G protein coupling switch that is prevented by ultra-low dose rimonabant.
Paquette JJ; Wang HY; Bakshi K; Olmstead MC
Behav Pharmacol; 2007 Dec; 18(8):767-76. PubMed ID: 17989514
[TBL] [Abstract][Full Text] [Related]
16. Effect of rimonabant on blood pressure in overweight/obese patients with/without co-morbidities: analysis of pooled RIO study results.
Ruilope LM; Després JP; Scheen A; Pi-Sunyer X; Mancia G; Zanchetti A; Van Gaal L
J Hypertens; 2008 Feb; 26(2):357-67. PubMed ID: 18192851
[TBL] [Abstract][Full Text] [Related]
17. Opioid antagonism of cannabinoid effects: differences between marijuana smokers and nonmarijuana smokers.
Haney M
Neuropsychopharmacology; 2007 Jun; 32(6):1391-403. PubMed ID: 17091128
[TBL] [Abstract][Full Text] [Related]
18. Rimonabant abolishes sensitivity to workload changes in a progressive ratio procedure.
Marusich JA; Wiley JL
Pharmacol Biochem Behav; 2012 Jun; 101(4):575-80. PubMed ID: 22425597
[TBL] [Abstract][Full Text] [Related]
19. Rimonabant effects on anxiety induced by simulated public speaking in healthy humans: a preliminary report.
Bergamaschi MM; Queiroz RH; Chagas MH; Linares IM; Arrais KC; de Oliveira DC; Queiroz ME; Nardi AE; Huestis MA; Hallak JE; Zuardi AW; Moreira FA; Crippa JA
Hum Psychopharmacol; 2014 Jan; 29(1):94-9. PubMed ID: 24424711
[TBL] [Abstract][Full Text] [Related]
20. Comparison of smoked marijuana and oral Delta(9)-tetrahydrocannabinol in humans.
Hart CL; Ward AS; Haney M; Comer SD; Foltin RW; Fischman MW
Psychopharmacology (Berl); 2002 Dec; 164(4):407-15. PubMed ID: 12457271
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
